Key result
Angiotensin II increases insulin sensitivity ~29% and muscle blood flow vs placebo, antagonized by irbesartan.
Why the study?
It is unclear whether the effects of angiotensin II on insulin sensitivity and skeletal muscle blood flow are mediated via subtype 1 receptors of angiotensin II.
Does Angiotensin II infusion alter muscle and renal blood flow and insulin sensitivity in healthy subjects, and are these effects mediated by AT1 receptors?
Population
9 healthy subjects, mean age 24 ± 2 years
Comparison
Placebo premedication plus placebo infusion vs angiotensin II infusion with or without irbesartan premedication
Design
Double-blind placebo-controlled randomized crossover study
Authors
Loading...
Ang II may enhance insulin sensitivity via AT1-mediated muscle vasodilation in healthy subjects; extends mechanistic insights into differential vascular effects.
RCT (n=9)
Double-blind
random order
Does Angiotensin II infusion alter muscle and renal blood flow and insulin sensitivity in healthy subjects, and are these effects mediated by AT1 receptors?
Absolute Event Rate: 9.3% vs 7.2%
p-value: p=< 0.05
Under hyperinsulinemic euglycemic conditions, Angiotensin II causes AT1-receptor-mediated vasodilation in skeletal muscle but vasoconstriction in renal vasculature.
Danilo Fliser (2000) conducted an RCT in Healthy (n=9). Angiotensin II vs. Placebo was evaluated on Insulin sensitivity (M-value, mg/kg/min) (p=< 0.05). Angiotensin II infusion significantly increased insulin sensitivity (9.3 vs 7.2 mg/kg/min) and muscle blood flow compared to placebo (p<0.05), effects that were antagonized by irbesartan.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: